PA
CMPR icon

PharVision Advisers’s Cimpress CMPR Stock Holding History

PharVision Advisers’s Portfolio CMPR Stock Details CMPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,885
Closed -$259K – 214
2025
Q4 		$259K Sell
3,885
-1,573
-29% -$107K 0.13% 373
2025
Q3 		$344K Buy
+5,458
New +$306K 0.19% 147

Other funds holding CMPR

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SHIM
Spruce House Investment Management New York $3.4B AUM 30.65% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Diamond Hill Capital Management
Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PharVision Advisers's CMPR Position: Q1 2026 in Review

PharVision Advisers sold out of Cimpress (CMPR) in Q1 2026, closing a stake of 3,885 shares — an estimated $259K sold.

PharVision Advisers first reported a position in CMPR in Q3 2025 and held it in 2 quarters. The position peaked at $344K in Q3 2025. 182 funds tracked by Wall St. Rank hold CMPR as of Q1 2026.

  • PharVision Advisers reported no remaining Cimpress position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 3,885 Cimpress shares in Q1 2026, an estimated $259K.
  • PharVision Advisers first reported a position in Cimpress in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Cimpress position peaked at $344K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Cimpress as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.